Endocrine Research Unit, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Endocrine Research Unit, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Arch Med Res. 2016 Oct;47(7):491-495. doi: 10.1016/j.arcmed.2016.11.009.
Cholesterol is a precursor of steroid hormones and an essential component of the cell membrane; however, altered regulation of the synthesis, absorption and excretion of cholesterol predispose to cardiovascular diseases of atherosclerotic origin. Despite the recognition of historical events for 200 years starting with Chevreul naming "cholesterine"; later on, Lobstein coining the term atherosclerosis and Marchand introducing it, Anichkov identifying cholesterol in atheromatous plaque, and Brown and Goldstein discovering LDL receptor (r-LDL), as well as the emergence of different drugs such as fibrates, statins and cetrapibs during this decade promising to increase HDL, and the most recent, ezetimibe and anti-PCSK9 to inhibit the degradation of r-LDL, morbidity has not been reduced in cardiovascular disease. To date, the controversy continues regarding the best and appropriate medical therapy for hypercholesterolemia; likewise, there is the recommendation of a healthy dietary content regarding the amount of sugar as well as the type of fats, either saturated or polyunsaturated. Together, control of circulating cholesterol, amelioration of hypertension, regulation of diabetes, and dietary recommendations might prevent atherosclerosis.
胆固醇是类固醇激素的前体,也是细胞膜的重要组成部分;然而,胆固醇的合成、吸收和排泄的调节异常会导致动脉粥样硬化性心血管疾病。尽管人们认识到从 Chevrel 命名“胆固醇”开始的 200 年历史事件;后来,Lobstein 创造了动脉粥样硬化这个术语,Marchand 引入了它,Anichkov 在动脉粥样硬化斑块中发现了胆固醇,Brown 和 Goldstein 发现了 LDL 受体(r-LDL),以及这十年中出现了不同的药物,如贝特类、他汀类和 cetrapibs,旨在增加 HDL,最近,ezetimibe 和抗 PCSK9 抑制 r-LDL 的降解,但心血管疾病的发病率并没有降低。迄今为止,关于高胆固醇血症的最佳和适当的医学治疗方法仍存在争议;同样,也有关于糖和脂肪类型(饱和或多不饱和)的健康饮食建议。总之,控制循环胆固醇、改善高血压、调节糖尿病和饮食建议可能预防动脉粥样硬化。